Deals Of The Week: Vertex/GSK, Vertex/Janssen, Boehringer Ingelheim/Ensemble
Executive Summary
Disparate events including Hurricane Sandy, extended-release generics, drug compounding and biopharma deal-making each highlighted just how important a challenge quality has become in the industry.
You may also be interested in...
Pharma Responds To Sandy’s Wrath With Delays
As the East Coast braces for the impact of Hurricane Sandy, companies choose the safety of their employees over keeping financial releases on schedule.
FDA’s Compounding Oversight: What Price Safety?
As meningitis outbreak widens, FDA and members of Congress are calling for clarification of what jurisdiction the agency has over pharmacies, but agency officials are stopping short of asking for clear new authorities.
FDA And Generic Drug Quality: Turning Point, Or Precipice?
OGD Director Geba says generic manufacturers still suffer from extensive quality problems, but GPhA officials argue the industry is doing fine and communications with the agency need to be more uniform.